Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Englumafusp alfa combinations in relapsed/refractory B-cell non-Hodgkin lymphoma
2022-502616-37-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, open-label trial of englumafusp alfa, obinutuzumab and glofitamab in mature B-cell lymphoma (3 arms), sponsored by Roche. Primary endpoints: Dose-limiting toxicities, Adverse events and 1 more. Planned start Jul 2019; status: authorised.
02
Drugs
englumafusp alfaobinutuzumabglofitamab
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on 2022-502616-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502616-37-00.